Loading...
•
Dec 31, 2020
Scholar Rock Q4 2020 Earnings Report
Scholar Rock reported full year financial results and highlighted business progress.
Key Takeaways
Scholar Rock reported a net loss of $86.5 million for the full year ended December 31, 2020. The company ended the year with approximately $341 million in cash, cash equivalents, and marketable securities.
TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).
SRK-181 DRAGON Phase 1 trial is enrolling patients with solid tumors in Part A.
A new U.S. patent was issued providing protection for broad therapeutic use of apitegromab.
The company ended 2020 with approximately $341 million in cash, cash equivalents, and marketable securities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...